FDA slots gene test for obesity drug into Class II
Published Date: 4/22/2026
Rule
Summary
The FDA is officially putting the Setmelanotide Eligibility Gene Variant Detection System into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also making it simpler for patients to get access to this cool new technology. The new rules took effect on April 22, 2026, but the classification applies retroactively to January 21, 2022, with no extra costs expected.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Test Reclassified to Class II
You may get easier access to a genetic test that finds people with obesity who could benefit from setmelanotide because the FDA classified the setmelanotide eligibility gene variant detection system as Class II (special controls). This final order is effective April 22, 2026 and the classification has been applied to the device as of January 21, 2022.
510(k) Premarket Notification Required
If you make or plan to market this test, the device is subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act because FDA has not exempted this device type. That means manufacturers must submit a 510(k) before marketing.
Classification Applies Retroactively
The FDA's Class II classification for the setmelanotide eligibility gene variant detection system is applied retroactively to January 21, 2022. The order itself is effective April 22, 2026.
Labeling and Performance Rules Required
Test labeling and any test report must include specific limiting statements and a detailed summary of performance testing. The labeling must say variant classifications reflect current science, variants may change classification (which can affect treatment eligibility), and, if applicable, that variants of uncertain significance (VUS) cannot be assigned pathogenicity.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in